Don't go by market cap, go stock-specific; pharma may be an outperformer: Sandip Sabharwal

Sandip Sabharwal recommended a company-specific strategy over midcap or largecap classifications in light of high market valuations, suggesting a 15% cash reserve. He discussed Birla's impact on the jewellery sector and praised Cipla’s quarterly performance. Sabharwal noted the potential for pharma stocks to outperform due to limited current investment in the sector.